deltatrials
Terminated PHASE2 INTERVENTIONAL 1-arm NCT02417753

AZD9150, a STAT3 Antisense Oligonucleotide, in People With Malignant Ascites

A Pilot Study of AZD9150, a STAT3 Antisense Oligonucleotide in Malignant Ascites

Sponsor: National Cancer Institute (NCI)

Conditions Ascites Gastrointestinal Cancer Gastrointestinal Neoplasms Ovarian Cancer Ovarian Neoplasms
Interventions AZD9150
Updated 7 times since 2017 Last updated: May 5, 2017 Started: Apr 3, 2015 Primary completion: Apr 7, 2016 Completion: Apr 7, 2016
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Study was closed because we could not find these types of patients.

Other terminated trials from National Cancer Institute (NCI)

See all terminations from National Cancer Institute (NCI)

Other Ascites trials with similar outcome

Browse all Ascites trials

Listed as NCT02417753, this PHASE2 trial focuses on Ascites and Gastrointestinal Cancer and remains terminated or withdrawn. Sponsored by National Cancer Institute (NCI), it has been updated 7 times since 2015, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotTerminated~Feb 2017 – ~Jul 2017 · 5 months · monthly snapshotTerminated~Jul 2017 – ~Jun 2018 · 11 months · monthly snapshotTerminated~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotTerminated~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotTerminated~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotTerminated~Sep 2024 – present · 22 months · monthly snapshotTerminated

Change History

7 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Terminated PHASE2

  4. Jun 2018 — Jan 2021 [monthly]

    Terminated PHASE2

  5. Jul 2017 — Jun 2018 [monthly]

    Terminated PHASE2

▶ Show 2 earlier versions

  1. Feb 2017 — Jul 2017 [monthly]

    Terminated PHASE2

  2. Jan 2017 — Feb 2017 [monthly]

    Terminated PHASE2

    First recorded

Apr 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Cancer Institute (NCI)
Data source: National Institutes of Health Clinical Center (CC)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations